The 2025 JP Morgan Healthcare Conference highlighted key trends shaping the biopharma landscape, including a resurgence in dealmaking driven by the urgency to address a looming $400 billion patent cliff. Industry leaders anticipate increased M&A activity and larger financing deals tied to critical testing milestones. Policy uncertainties under the Trump administration, including potential revisions to the Inflation Reduction Act and regulatory policies, add complexity to the outlook. Chinese innovation is gaining momentum, contributing a third of pharma licensing deals last year, while AI continues to revolutionize drug development, despite challenges in accessing high-quality data.
5 Insights From The 2025 JP Morgan Healthcare Conference (Forbes)
0